ArticleInternational journal of women's health2026
Self-Reported Experiences of Women Taking Hormonal Treatments for Their Endometriosis and Uterine Fibroids Symptoms: Results from a Real-World Study in the US (MyEndoUF).
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To characterize the experiences of individuals taking hormonal therapies to manage their symptoms of endometriosis (EM) or uterine fibroids (UF). Patients and Methods: This prospective, 16-week observational study enrolled US participants who self-reported having received an EM or UF diagnosis. Participants used an online platform to complete daily, weekly, and monthly surveys to self-report menstrual bleeding severity, EM or UF-associated pain severity, pain medication use, hormonal therapy changes, procedures for EM/UF, and work and productivity impairment. Results were analyzed descriptively and reported for the EM and UF cohorts separately. Results: Of 411 participants, 185 had an EM and 226 had a UF diagnosis. Mean age (standard deviation [SD]) was 34.9 (7.4) and 37.5 (7.7) years in the EM and UF cohorts, respectively. Participants with EM and UF reported first heavy menstrual bleeding at 14.0 (interquartile range [IQR] 13.0, 18.0) and 19.5 (IQR 13.0, 32.0) years of age, respectively, and first pelvic pain during menses at 15.0 years of age (IQR: EM 13.0, 18.0; UF 13.0, 23.3). During the study period, 17.7% of observed days were bleeding days, most commonly spotting. Pelvic pain was rated as mild, with a median score of 3.4 (1.0, 5.0) and 2.7 (1.3, 4.4) for dysmenorrhea and 1.3 (0.4, 2.7) and 1.5 (0.3, 3.8) for non-menstrual pelvic pain for EM and UF, respectively. In both cohorts, the most frequently used hormonal treatments were combined contraceptive pills and levonorgestrel intrauterine devices, with most participants having received their current treatments for >2 years. Hormonal treatment switching or discontinuation during the study was low. Pain medication use, most frequently over-the-counter medications, was higher on bleeding days. Absenteeism, presenteeism, and work impairment scores were higher during bleeding versus non-bleeding weeks. Conclusion: In this observational study of individuals with EM and UF using hormonal therapy, participants reported mild symptoms, with increased pain medication use and work impairment during periods. Bleeding abnormalities and period pain appeared early in life, which could represent potential indicators for EM and UF, warranting further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.